MINDCURE will distribute these protocols to therapists through iSTRYM, its digital therapeutics platform. This milestone in protocol development unlocks the company’s protocol distribution platform in time for iSTRYM’s clinical MVP launch in Q3 2021. VANCOUVER, BC, June 17, 2021 /CNW/ – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ( “MINDCURE” or the “Company”), a leader in advanced…


Previous articlePsilocybin for Depression: A Q&A between Robin Carhart-Harris & a Psilocybin Study Participant
Next articlePsyence Group Announces Collaboration with the Scientific Research Council (SRC) of Jamaica for Psilocybin Product Development